Skip to main content

Recent News

  • Dec 01, 2023
    RheumNow Podcast square

    Dr. Jack Cush reviews this past week's news and journal reports from RheumNow.com. Good news is that nearly 99% of adult rheumatology positions matched! But the challenge is that 45% of pediatric fellowship programs and 39% of pediatric rheum slots were unfilled in the 2024 NRMP match.

    Read Article

ICYMI: Sex bias in RA: time to stop blaming hormones?

Whether it’s RA, SLE or Sjogren’s, the increased prevalence of females affected by auto-immune diseases is well established, yet not fully understood. Often, I have heard that sexual hormones are responsible for every aspect of it. Two abstracts presented this year question this paradigm.

Read Article
Dr. Jack Cush reviews key Still's disease abstracts from EULAR 2023 https://t.co/6d4WKT3oFS https://t.co/ITwK6kVsmZ
Dec 01, 2023
UKs MHRA issued a safety alert #MTX maybe associated w/ photosensitivity. Based on Coroners death (by secondary infx) report assoc w/ photosensitivity Rxn in a MTX Rx pt. Warning is because this is not a well-known side effect https://t.co/Vbl9BYMMNC https://t.co/9SyYQMTXTl https://t.co/JNqvNieqrt
Dec 01, 2023
Chemokine CXCL10 a potential biomarker for ILD in systemic sclerosis (SSc)? Study of 165 SSc pts (41 w/ SSc-ILD) found higher serum CXCL10 in SSc-ILD (126 vs. 78.5 pg/ml). Hi levels incr risk of ILD 2.74-fold. Most CXCL10 from inflammed lung tissues https://t.co/Z8pIAZYaC0 https://t.co/ErRsD9Msn1
Dec 01, 2023

ICYMI: Do Probiotics Improve Psoriatic Arthritis?

Nov 30, 2023

Psoriatic arthritis and the gut microbiome have become more intertwined, especially in the past few years. It was to my amazement that one of the first abstracts I came across was the effect of probiotic modulation on gut dysbiosis and disease activity in psoriatic arthritis patients. 

Read Article

Rheum Fellowship Slots Fill Up for 2024

Nov 30, 2023

While adult rheumatology programs continue to have high match rates, pediatric rheumatology programs remain less popular.The National Residency Matching Program announced yesterday that the 2024 rheumatology fellowship match filled 97.6% (124/127) of programs, and 98.9% (273/276) of rheumatology fellowship positions. This is on par with last years (2023) adult rheumatology match wherein 97.8% (265/271) of the rheumatology fellow positions

Read Article
Study from British Columbia, Canada, showed between 2010 & 2020, they saw 31% more new pt rheum consults (149,902); 1st time consults for inflammatory arthritis incr 28% to 51%. While time to 1st visit decr. 35%, time to DMARD initiation was unchanged https://t.co/Et7GzxKeNe https://t.co/2as2YuIV4d
Nov 30, 2023
Watch: Effects of Apremilast on Cardiometabolic Effects in PsA https://t.co/aKMxEfbc4c https://t.co/wjcEjLtlaC
Nov 30, 2023
NEW Health Policy—Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline https://t.co/WYNcVigb7n Free to read with registration on https://t.co/28wkm59DgB https://t.co/Qbm1y76o3E
Real World Experience with PEXIVAS Low Steroid Taper Dr. Mike Putman discusses abstract 0725 with Dr. Sophie Nagle at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/lXTyb93ata https://t.co/kC6J9Zuurf
Nov 30, 2023
What do you think of the concept of "dysuricemia" - the concept that both hyperuricemia and hypouricemia influence diseases. “The lower, the better” is incorrect; the ideal is to maintain normouricemia, or optimal SU level, to reduce the urate burden https://t.co/Vi9htWTNwr https://t.co/fsx9Oq08Ak
Nov 30, 2023
Reconsidering Steroids Not one of us in rheumatology hasn’t prescribed steroids, but we need to reconsider how much/how often we use them. In almost every disease state we treat, we are seeing progression towards lesser and shorter courses . https://t.co/VRlCeNXyKR https://t.co/k5Uy7IHr3h
Nov 30, 2023
TNFi and RA-ILD – The Pendulum Swings Again Tumour necrosis factor inhibitors (TNFi) revolutionised the treatment of rheumatoid arthritis. They heralded the wave of advanced therapies, which has transformed the treatment landscape in rheumatic disease. https://t.co/zBwJKyDihL https://t.co/uCLnmaLC9j
Nov 30, 2023
Single center obs. study 74 RA-ILD pts Rx w/ antifibrotics (40 nintedanib; 34 pirfenidone); F/U 89 wks, had signif improvement in FVC estimated decline after antifibrotics (-0.3% w/ vs -6.2% w/o). 35% died, 4 lung transplants. 55% AEs, 46% D/C Rx https://t.co/s6O5uU3z2i
Nov 30, 2023
#ACR23 Abst#1629 from FORWARD registry showed RA pts (n667) with LONG COVID (15%) had worse RA pre-COVID and post-infx, and had worse COVID (more ABx & hospitalization). RA-long Covid pts had 3fold more fibromyalgia (13 vs 41%) https://t.co/VFNAnSxNzN https://t.co/WLqmdM3Nn2
Nov 30, 2023

Next generation JAK-inhibition strategies

It has been just over a decade since the approval of tofacitinib (JAK1/JAK3-inhibitor) by the US FDA for the treatment of rheumatoid arthritis. Since then, baricitinib (JAK1/JAK2-i), filgotinib and upadacitinib (both selectively targeting JAK1) also have been licensed for the treatment of rheumatoid arthritis. As there are many more JAK-inhibitors evaluated in clinical trials currently, how do you stand out?

Read Article
Watch: No Increased Mortality in Patients with RA Receiving Checkpoint Inhibitors Dr. Mike Putman discusses abstract 1071 with Dr. Madeline O'Sullivan at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/YdIlhLf5gh https://t.co/6dfWHakboh
Nov 29, 2023
ACR Daily Recap - MONDAY Panelists: Drs. Kathryn Dao, Michael Putman and Eric Dein Moderator: Dr. Jack Cush https://t.co/b1k1gsHI2z https://t.co/BWu7GXFxhj
Nov 29, 2023
IgG4 disease- the WInS withdrawal study results https://t.co/rg0YJ0LlZM https://t.co/L6SzcD7QlJ
Nov 29, 2023
Theres a ustekinumab biosimilar, CT-P43 - In a multinational, phase III study in 509 plaque psoriasis pts, CT-P43 was equivalent to the originator, Stelara, with week 16 PASI75 scores of 78% vs 76%, and continued efficacy out to week 40 https://t.co/dEImEp8l90 https://t.co/UoqGgaad8H
Nov 29, 2023
×